MEBGEN™ BRAF Kit Receives MHLW Approval as Companion Diagnostic for Use with Patients with Melanoma
Products
Medical and Biological Laboratories Co., Ltd. (“MBL”), a JSR Life Sciences Company, announced that MEBGEN™ BRAF Kit, an in vitro diagnostic reagent, was approved for detection of BRAF gene mutations (V600E or V600K) by the Ministry of Health, Labour and Welfare (MHLW) for production and marketing in Japan on July 7, 2022.
MEBGEN™ BRAF Kit was developed as a companion diagnostic for multiple anti-cancer agents in melanoma. The MEBGEN™ BRAF Kit is expected to be an important clinical diagnostic in guiding personalized medicine for patients with melanoma.
For more information, please visit the MBL’s release page below.